ANNX
Annexon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.87
+0.62%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-8.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 12, 2026 | Blumenkranz Mark S. · director | A-Award | 175,000 | $5.39 |
| Jun 15, 2026 | Choi Jung · director | A-Award | 65,000 | $4.70 |
| Jun 15, 2026 | Carson William H. · director | A-Award | 65,000 | $4.70 |
| Jun 15, 2026 | Yednock Ted · officer: EVP & CHIEF INNOVATION OFFICER | M-Exempt | 30,646 | $1.85 |
| Jun 15, 2026 | Cockroft Bettina M. · director | A-Award | 65,000 | $4.70 |
| Jun 15, 2026 | Waddill William D. · director | A-Award | 65,000 | $4.70 |
| Jun 15, 2026 | Satter Muneer A · director | A-Award | 65,000 | $4.70 |
| Jun 15, 2026 | JONES WILLIAM A JR · director | A-Award | 65,000 | $4.70 |
| May 29, 2026 | Satter Muneer A · director | Purchase | 613,497 | $5.41 |
| May 13, 2026 | Carson William H. · director | Purchase | 8,000 | $5.78 |
| Apr 14, 2026 | Carson William H. · director | Purchase | 8,000 | $6.20 |
| Mar 12, 2026 | Carson William H. · director | Purchase | 8,000 | $5.67 |
| Mar 4, 2026 | ARTIS DEAN RICHARD · officer: EVP & CHIEF SCIENTIFIC OFFICER | Sale | 5,894 | $5.43 |
| Mar 4, 2026 | Yednock Ted · officer: EVP & CHIEF INNOVATION OFFICER | Sale | 5,566 | $5.42 |
| Mar 4, 2026 | Lew Jennifer · officer: EVP & CHIEF FINANCIAL OFFICER | Sale | 5,565 | $5.42 |
| Mar 4, 2026 | Dananberg Jamie · officer: CHIEF MEDICAL OFFICER | Sale | 5,820 | $5.43 |
| Mar 4, 2026 | Overdorf Michael · officer: EVP & CHIEF BUSINESS OFFICER | Sale | 4,339 | $5.42 |
| Feb 23, 2026 | ARTIS DEAN RICHARD · officer: EVP & CHIEF SCIENTIFIC OFFICER | A-Award | 62,500 | $0.00 |
| Feb 23, 2026 | Overdorf Michael · officer: EVP & CHIEF BUSINESS OFFICER | A-Award | 62,500 | $0.00 |
| Feb 23, 2026 | Overdorf Michael · officer: EVP & CHIEF BUSINESS OFFICER | A-Award | 250,000 | $5.10 |
| Feb 23, 2026 | Dananberg Jamie · officer: CHIEF MEDICAL OFFICER | A-Award | 225,000 | $5.10 |
| Feb 23, 2026 | Dananberg Jamie · officer: CHIEF MEDICAL OFFICER | A-Award | 56,250 | $0.00 |
| Feb 23, 2026 | ARTIS DEAN RICHARD · officer: EVP & CHIEF SCIENTIFIC OFFICER | A-Award | 250,000 | $5.10 |
| Feb 23, 2026 | Yednock Ted · officer: EVP & CHIEF INNOVATION OFFICER | A-Award | 62,500 | $0.00 |
| Feb 23, 2026 | Yednock Ted · officer: EVP & CHIEF INNOVATION OFFICER | A-Award | 250,000 | $5.10 |
| Feb 23, 2026 | Lew Jennifer · officer: EVP & CHIEF FINANCIAL OFFICER | A-Award | 62,500 | $0.00 |
| Feb 23, 2026 | Lew Jennifer · officer: EVP & CHIEF FINANCIAL OFFICER | A-Award | 250,000 | $5.10 |
| Feb 23, 2026 | Love Douglas · director, officer: PRESIDENT AND CEO | A-Award | 1,250,000 | $5.10 |
| Feb 20, 2026 | Overdorf Michael · officer: EVP & CHIEF BUSINESS OFFICER | Sale | 6,225 | $5.10 |
| Feb 20, 2026 | Yednock Ted · officer: EVP & CHIEF INNOVATION OFFICER | Sale | 7,857 | $5.11 |
Institutional positioning
13F filings over the trailing two quarters
New 67Increased 87Reduced 54Sold out 212
| Filer | Action | Shares | Filed |
|---|---|---|---|
| REDMILE GROUP, LLC | Increased | 14,549,768 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 10,938,509 | May 13, 2026 |
| FMR LLC | Increased | 10,635,648 | May 15, 2026 |
| BVF INC/IL | Reduced | 8,698,173 | May 15, 2026 |
| STATE STREET CORP | Increased | 6,919,255 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 5,956,589 | May 15, 2026 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Reduced | 5,212,674 | May 15, 2026 |
| BELLEVUE GROUP AG | Unchanged | 5,157,290 | May 15, 2026 |
| MAK CAPITAL ONE LLC | Increased | 4,724,043 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Reduced | 4,300,000 | May 15, 2026 |
| BANK OF AMERICA CORP /DE/ | Increased | 4,259,995 | May 18, 2026 |
| NUVEEN, LLC | Increased | 4,246,330 | Apr 30, 2026 |
| SIREN, L.L.C. | New Position | 3,958,646 | May 14, 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | Increased | 3,886,909 | May 15, 2026 |
| AMERIPRISE FINANCIAL INC | Reduced | 3,449,121 | Jul 17, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 12, 2026